Parathyroid Hormone-Related Protein (PTHrP)
Evidence: B/C — Meaningful Human EvidenceEndocrine / Calcium-Bone Axis Signaling
Evidence Snapshot
What this grade covers
B applies to PTHrP's discovery science and its human disease-association evidence (humoral hypercalcemia of malignancy). C applies to any direct-administration-efficacy claim for native PTHrP, since direct human administration/intervention evidence for native PTHrP itself is limited; the most robust direct-administration evidence in this pathway belongs to the firewalled analogue Abaloparatide, not to this subject.
Regulatory Context
Native PTHrP is an endogenous paracrine/autocrine protein with no approved product of its own. The synthetic PTHrP(1-34) analogue Abaloparatide (Tymlos) is FDA-approved and separately documented; its evidence must not be read as native-PTHrP evidence.
Research Takeaway
PTHrP (PTHLH gene product) is a native paracrine/autocrine signaling protein sharing significant N-terminal sequence homology with PTH but arising from a distinct gene. It was originally isolated via its role in a paraneoplastic hypercalcemic syndrome.
See all 4 evidence claims →Quick Summary
PTHrP is a hormone-like signaling protein related to PTH, best known clinically for its role in cancer-related high calcium (humoral hypercalcemia of malignancy). A synthetic analogue drug, Abaloparatide, is built on part of its sequence but is a separate, firewalled subject.
Mechanism & Research Overview
PTHrP is a hormone-like signaling protein related to PTH, best known clinically for its role in cancer-related high calcium (humoral hypercalcemia of malignancy). A synthetic analogue drug, Abaloparatide, is built on part of its sequence but is a separate, firewalled subject.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
PTHrP (PTHLH gene product) is a native paracrine/autocrine signaling protein sharing significant N-terminal sequence homology with PTH but arising from a distinct gene. It was originally isolated via its role in a paraneoplastic hypercalcemic syndrome.
Sources: A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression
Supported
PTHrP activates the same PTH1 receptor as PTH (PTH1R), explaining overlapping downstream effects on bone and renal calcium handling despite being distinct gene products.
Supported
Tumor-secreted PTHrP is the principal mediator of humoral hypercalcemia of malignancy (HHM), a paraneoplastic hypercalcemic syndrome most commonly associated with squamous-cell and certain other carcinomas.
Supported
Abaloparatide is a synthetic analogue of PTHrP(1-34), not native PTHrP itself; its own clinical-trial and regulatory evidence belongs to a separate, firewalled MitoCore subject.
Sources: TYMLOS (abaloparatide) injection — FDA Prescribing Information
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Much of the direct human disease-association evidence for PTHrP comes from cancer/humoral-hypercalcemia contexts; this does not establish PTHrP's behavior in non-malignant physiology as equally well characterized in this source base.
Research Areas Being Studied
Research areas discussed on this page reflect the Endocrine / Calcium-Bone Axis Signaling category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression (1987):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression | 1987 | Primary molecular cloning and expression of PTHrP: a prepro-peptide of 36 amino acids and mature protein of 141 amino acids with significant N-terminal homology to PTH, discovered via its role in humoral hypercalcemia of malignancy. Distinct gene (PTHLH) from PTH. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| TYMLOS (abaloparatide) injection — FDA Prescribing Information | Abaloparatide is a synthetic 34-amino-acid analogue of PTHrP(1-34), sharing 76% sequence homology with native human PTHrP(1-34) and 41% homology with PTH(1-34); molecular formula C174H300N56O49; acts as a PTH1 receptor agonist. FDA-approved (Tymlos) for postmenopausal women with osteoporosis at high fracture risk and, per current labeling, for men with osteoporosis at high fracture risk (2025 expansion). ANALOGUE_PROGRAM_CONTEXT relative to native PTHrP — this regulatory/identity evidence is specific to the synthetic analogue and must not be read as native-PTHrP evidence. | No source link available |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Paraneoplastic humorally mediated hypercalcemia induced by parathyroid hormone-related protein in gynecologic malignancies: a systematic review | 2009 | Systematic review establishing tumor-secreted PTHrP as the principal mediator of humoral hypercalcemia of malignancy (HHM), most commonly with squamous-cell and certain other carcinomas. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research and official regulatory information about PTHrP and does not provide medical advice, an individualized treatment recommendation, or dosing instructions.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for Parathyroid Hormone-Related Protein (PTHrP)
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.